We now have two FDA-approved disease-modifying treatments for Alzheimer's disease, and hundreds of clinical trials are ...

for early Alzheimer’s disease (AD). This decision may simplify the treatment process for patients and care partners. LEQEMBI, designed for patients with mild cognitive impairment (MCI) or mild ...

Fact checked by Nick Blackmer The Food and Drug Administration (FDA) has approved a new maintenance dosing schedule for ...

Once every four weeks maintenance dosing may be easier for patients and care partners to continue treatmentAlzheimer's disease progression does ...

Early research suggests GLP-1 drugs could prevent or treat Alzheimer's Disease. Results from a big clinical trial could soon ...

Topline data were published from a phase 2b/3 study evaluating blarcamesine for the treatment of early Alzheimer disease.

Lecanemab is a humanized immunoglobulin gamma 1 monoclonal antibody directed against aggregated soluble and insoluble forms of amyloid beta.

The FDA approves a new maintenance dosing regimen for lecanemab (Leqembi; Eisai) in patients with early-stage Alzheimer ...

The next Alzheimer’s treatment could come from an unexpected place. In new research released this week, scientists have found ...

New research uncovers how declining protein clearance mechanisms with age lead to Alzheimer’s, Parkinson’s, and other ...

MEMORY loss is widely considered the most well-known symptom of dementia – and it’s often the first noticeable sign in the ...